Serum CA 19 - 9 and CA 72 - 4 levels in hashimoto's thyroiditis: a prospective case-control study.

IF 3.3 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Huseyin Demirci, Enes Ucgul, Ebru Aydogan, Huriye Unal
{"title":"Serum CA 19 - 9 and CA 72 - 4 levels in hashimoto's thyroiditis: a prospective case-control study.","authors":"Huseyin Demirci, Enes Ucgul, Ebru Aydogan, Huriye Unal","doi":"10.1186/s12902-025-02037-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hashimoto's thyroiditis is a common autoimmune thyroid disorder and a leading cause of subclinical hypothyroidism. Tumor markers such as CA 19 - 9 and CA 72 - 4 may also be elevated in certain benign inflammatory conditions. This study aimed to investigate the levels of CA 19 - 9 and CA 72 - 4 in patients with subclinical hypothyroidism due to Hashimoto's thyroiditis and to evaluate the effects of levothyroxine treatment.</p><p><strong>Methods: </strong>This prospective case-control study included 30 patients with subclinical hypothyroidism due to Hashimoto's thyroiditis and 30 healthy controls matched by age and sex. Serum levels of CA 19 - 9, CA 72 - 4, TSH, free T4, TPOAb, and TgAb were measured at baseline and after 6 weeks of levothyroxine therapy. Additionally, correlations between tumor markers and thyroid function parameters were analyzed.</p><p><strong>Results: </strong>Initially, there were no significant differences in CA 19 - 9 and CA 72 - 4 levels between the patient and control groups. Following treatment, a significant decrease in CA 19 - 9 levels was observed in patients who achieved euthyroidism (p = 0.020), whereas no significant change was detected in CA 72 - 4 levels.</p><p><strong>Conclusions: </strong>CA 19 - 9 and CA 72 - 4 levels do not appear to differ significantly between patients with subclinical hypothyroidism due to Hashimoto's thyroiditis and healthy individuals. However, CA 19 - 9 levels may decrease upon restoration of euthyroidism, potentially reflecting a reduction in thyroid-related inflammation. Further studies with larger cohorts and longer follow-up periods are warranted to confirm and clarify these observations.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"217"},"PeriodicalIF":3.3000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Endocrine Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12902-025-02037-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hashimoto's thyroiditis is a common autoimmune thyroid disorder and a leading cause of subclinical hypothyroidism. Tumor markers such as CA 19 - 9 and CA 72 - 4 may also be elevated in certain benign inflammatory conditions. This study aimed to investigate the levels of CA 19 - 9 and CA 72 - 4 in patients with subclinical hypothyroidism due to Hashimoto's thyroiditis and to evaluate the effects of levothyroxine treatment.

Methods: This prospective case-control study included 30 patients with subclinical hypothyroidism due to Hashimoto's thyroiditis and 30 healthy controls matched by age and sex. Serum levels of CA 19 - 9, CA 72 - 4, TSH, free T4, TPOAb, and TgAb were measured at baseline and after 6 weeks of levothyroxine therapy. Additionally, correlations between tumor markers and thyroid function parameters were analyzed.

Results: Initially, there were no significant differences in CA 19 - 9 and CA 72 - 4 levels between the patient and control groups. Following treatment, a significant decrease in CA 19 - 9 levels was observed in patients who achieved euthyroidism (p = 0.020), whereas no significant change was detected in CA 72 - 4 levels.

Conclusions: CA 19 - 9 and CA 72 - 4 levels do not appear to differ significantly between patients with subclinical hypothyroidism due to Hashimoto's thyroiditis and healthy individuals. However, CA 19 - 9 levels may decrease upon restoration of euthyroidism, potentially reflecting a reduction in thyroid-related inflammation. Further studies with larger cohorts and longer follow-up periods are warranted to confirm and clarify these observations.

桥本甲状腺炎患者血清ca19 - 9和ca72 - 4水平:一项前瞻性病例对照研究。
背景:桥本甲状腺炎是一种常见的自身免疫性甲状腺疾病,是亚临床甲状腺功能减退的主要原因。肿瘤标志物如CA 19 - 9和CA 72 - 4也可能在某些良性炎症条件下升高。本研究旨在探讨桥本甲状腺炎亚临床甲状腺功能减退患者CA 19 - 9和CA 72 - 4的水平,并评价左旋甲状腺素治疗的效果。方法:本前瞻性病例对照研究纳入30例桥本甲状腺炎亚临床甲状腺功能减退患者和30例年龄、性别匹配的健康对照。在基线和左旋甲状腺素治疗6周后测定血清CA 19 - 9、CA 72 - 4、TSH、游离T4、TPOAb和TgAb水平。此外,还分析了肿瘤标志物与甲状腺功能参数的相关性。结果:最初,患者与对照组之间CA 19 - 9和CA 72 - 4水平无显著差异。治疗后,实现甲状腺功能亢进的患者CA 19 - 9水平显著下降(p = 0.020),而CA 72 - 4水平无显著变化。结论:CA 19 - 9和CA 72 - 4水平在桥本甲状腺炎引起的亚临床甲状腺功能减退患者和健康人之间没有明显差异。然而,CA 19 - 9水平可能会随着甲状腺功能亢进的恢复而降低,这可能反映了甲状腺相关炎症的减少。进一步的研究需要更大的队列和更长的随访期来证实和澄清这些观察结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Endocrine Disorders
BMC Endocrine Disorders ENDOCRINOLOGY & METABOLISM-
CiteScore
4.40
自引率
0.00%
发文量
280
审稿时长
>12 weeks
期刊介绍: BMC Endocrine Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of endocrine disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信